VJOncology is committed to improving our service to you

ESMO 2019 | Initial EV-103 results: enfortumab vedotin plus pembrolizumab for urothelial carcinoma

VJOncology is committed to improving our service to you

Christopher Hoimes

Christopher Hoimes, MD, PhD, of University Hospitals Seidman Cancer Center, Cleveland, OH, presents the initial results of the EV-103 trial of enfortumab vedotin plus pembrolizumab for locally advanced for metastatic urothelial carcinoma (NCT03288545). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter